Clinical trial Recruiting at 2 sites Interventional Ages 18 and up

Analysis of blood tumor markers for cancer diagnosis and treatment monitoring

Official title: Analysis of Circulating Tumor Markers in Blood

Run by Institut du Cancer de Montpellier - Val d'Aurelle · NCT04025541 · Data updated 2026-11-12

This study is testing whether a simple blood test can replace traditional tissue biopsies to help diagnose cancer and monitor how well treatments are working.

More Breast Cancer trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment992 (estimated)
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
Academic / other
Drugs / interventionschemotherapy
Locations2 sites (Montpellier and 1 other locations)
StatusRecruiting
StartedMay 29, 2018
Main results expectedMay 29, 2029
Study endsMay 29, 2032
Registry record updatedNovember 9, 2026
Trial IDNCT04025541 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older with invasive tumor pathology, whether confirmed or suspected.

Probably not a fit

Patients who are unable to maintain regular follow-up due to psychological, family, social, or geographical reasons may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on the analysis of circulating tumor markers found in the blood, aiming to replace traditional tissue biopsies with a simpler blood test known as liquid biopsy. It investigates the diagnostic, prognostic, and predictive potential of these biomarkers, particularly in response to various medical interventions such as chemotherapy and surgery. By utilizing small cohorts for different clinical situations, the study seeks to generate feasibility data and proof of concept, which could pave the way for larger studies in the future.

Why it matters

Potential benefit: If successful, this approach could provide a less invasive method for diagnosing and monitoring cancer treatment effectiveness.

How similar studies have gone: While the concept of liquid biopsies is gaining traction, this specific approach focusing on the kinetics of blood markers in response to clinical events is relatively novel and underexplored.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
2. Man or woman ≥ 18 years,
3. Obtaining of the informed consent signed before any procedure of specific preselection on approval.

Exclusion Criteria:

1. Private persons of freedom or under guardianship,
2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
3. Pregnant woman and/or breast-feeding,
4. Unaffiliated patient to Social Protection System,

Where it's running

  • Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
    Montpellier, France
    Recruiting
  • Icm
    Montpellier, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.